Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 11, 2018

View Archived Issues

Jeil Pharmaceutical begins phase I trial of oral JP-1366

Retrophin and Censa Pharmaceuticals to collaborate on CNSA-001 for PKU

Horizon Pharma licenses MEDI-4945 from MedImmune

Appili Therapeutics obtains rights to F. tularensis vaccine

Cypralis gains exclusive rights to certain cyprolides from Gilead collaboration

Idorsia describes discovery and structure of T-type calcium channel blocker ACT-709478

Caladrius studies CLBS-12 in patients with critical limb ischemia

Phase I study explores use of iC9-CAR19 in relapsed or refractory ALL

Patient enrollment ongoing in phase I trial of TTC-352 for breast cancer

Latest follow-up data from phase Ia trial of ProscaVax

KA34 to enter clinical testing for the treatment of osteoarthritis

Collegium Pharmaceutical enters agreement to commercialize Nucynta in U.S.

FDA gives orphan drug status to Avadel's FT-218 for narcolepsy

Stem cell-derived CAR T-cells persist in simian/human immunodeficiency virus model

MedDay Pharmaceuticals reviews pipeline at J.P. Morgan meeting

Twelve-month interim data show sustained IOP reduction with Glaukos' iDose travoprost

Shionogi and PharmaIN establish research collaboration

Phase I study of AlphaMedix begins in U.S.

Skin organoids derived from pluripotent stem cells display hair folliculogenesis

Sublingual allergy immunotherapy tablet Odactra now available in U.S.

Nagoya City University, University of Tokyo patent mutant SOD1/derlin-1 interaction inhibitors

FDA grants orphan status to eflornithine/sulindac combination for pancreatic cancer

Novel estrogen receptor modulators identified at Roche and Genentech

AstraZeneca's Fasenra approved in E.U.

Bristol-Myers Squibb discovers apelin receptor agonists

Incyte discloses novel PD-1/PD-L1 interaction inhibitors

Merck & Co. presents new histone deacetylase 6 inhibitors

Ferring and Chinese Academy of Sciences announce collaboration in reproductive medicine

Applied Genetic Technologies opens phase I/II study of AGTC-501 in X-linked retinitis pigmentosa

Galapagos obtains rights to MALT1 inhibitors for inflammatory and/or oncological diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...